Zusammenfassung
Betarezeptorenblocker spielen eine wichtige Rolle bei der Behandlung kardiovaskulärer Erkrankungen. Hauptindikationen sind arterielle Hypertonie, koronare Herzkrankheit, tachykarde Herzrhythmusstörungen und chronische Herzinsuffizienz. Wichtigste Gruppe sind die β1-selektiven Betarezeptorenblocker.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Bristow MR (2000): β-Adrenergic receptor blockade in chronic heart failure. Circulation 101: 558–569.
Bowman AJ, Chen CP, Ford GA (1994): Nitric oxide mediated venodilator effects of nebivolol. Brit J Clin Pharmacol 38:199–204.
Brodde OE (1991): Beta 1-and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203–242.
Chobanian AV, Bakris GL, Black HR, et al (2003): Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). Hypertension 42:1206–1252. http://www.nhlbi.nih.gov/guidelines/hypertension/.
CIBIS II Study (1999): The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 353: 9–13.
Dargie HJ (2003): β-Blockers in heart failure. Lancet 362:2–3.
Deutsche Liga zur Bekämpfung des hohen Blutdrucks/Deutsche Hochdruckliga (2003): Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie. http://www.paritaet.org/hochdruckliga/Leit2003.htm.
Eschenhagen T (2004): Herzinsuffizienz. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer, Heidelberg New York, S. 223–258.
Frishman WH, Kostis J, Strom J, Hossler M, Ekayam U et al (1979): Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6: A comparison of pindolol and propranolol in the treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity. Am Heart J 98: 526–535.
Ijzerman AP, Soudijn W (1989): The antiarrhythmic properties of β-adrenoceptor antagonists. Trends Pharmacol Sci 10:31–36.
Kilbinger H, Rahn K-H (2004): Hypertonic In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer, Berlin Heidelberg New York, S. 209–226.
Meier K, Lemmer B (2004): Blood pressure and heart rate after metoprolol or nebivolol and effects on nitric oxide urinary excretion in spontaneously hypertensive rats with and without 1-NAME. Z Kardiol/Germ J Cardiol 93(Suppl 3): P1320.
MERIT-HF Study (1999): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353:2001–2007.
Packer M, Coats AJS, Fowler MB, Katus HA et al (2001): Effect of Carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658.
Pesant Y, Marc-Aurele J, Bielmann P, Alaupovic P, Cartier P, Bichet D, et al (1999): Metabolic and antihypertensive effects of nebivolol and atenolol in normome-tabolic patients with mild-to-moderate hypertension. Am J Ther 6:137–147.
Poirier L, Cléroux J, Nadeau A, Lacourcière Y (2001): Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 19:1429–1435.
Poole-Wilson PA, Svedberg K, Geland JGF, Lenarda A, Hanrath P, Komajda M et al (2003): Comparison of Carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7–13.
Poynard T, Calés P, Pasta L, Ideo G, Pascal J-P et al and the Franco-Italian Multi-center Study Group (1991): Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 324:1532–1538.
Quyyumi AA, Wright C, Mockus L, Fox KM (1984): Effect of partial agonist activity in β-blockers in severe angina pectoris: A double blind comparison of pindolol and atenolol. Brit Med J 289: 951–953.
Ruf G, Trenk D, Jahnchen E, Roskamm H (1994): Determination of the anti-ischemic activity of nebivolol in comparison with atenolol. Int J Cardiol 43: 279–285.
Schrör K, Kelm M (2004): Koronare Herzkrankheit. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer Verlag, Berlin Heidelberg New York, S. 259–275.
Tzemos N, Lim PO, MacDonald TM (2001): Nebivolol reverses endothelial dysfunction in essential hypertension: a randomised, double-blind, crossover study. Circulation 104: 511–514.
Van Nueten L, Taylor FR, Robertson JI (1998): Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 12: 135–140.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lemmer, B. (2004). Betarezeptorenblocker. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-18513-7_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21359-8
Online ISBN: 978-3-642-18513-7
eBook Packages: Springer Book Archive